Screening For Breast, Cervical And Ovarian Cancers
The BRCA genes are part of your body’s natural defense system. They help protect you from developing cancer.
Why BRCA genes are important
If you have a BRCA gene that is not working properly (meaning, it carries a harmful variant), your lifetime risk of developing breast, ovarian and other cancers increases significantly.
BRCA is a screening test that identifies variants in 26 genes, including BRCA1 and BRCA, which are associated with increased risk for developing breast and other cancer types.
additional test details
BRCA test screens these 26 genes:
- ATM
- CDH1
- MRE11A
- PMS2
- TP53
- BARD1
- CHEK1
- MSH2
- PTEN
- XRCC2
- BLM
- EPCAM
- MSH6
- RAD50
- BRCA1
- FAM175A
- MUTYH
- RAD51C
- BRCA2
- MEN1
- NBN
- RAD51D
- BRIP1
- MLH
- PALB2
- STK11
These genes may be associated with increased risk for:
Hereditary cancer syndromes
- Hereditary cancer syndromes
- Cowden syndrome
- Li-Fraumeni Syndrome
- Peutz-Jeghers Syndrome
- Lynch Syndrome
- Gastric cancer + others
Cancer types
- Colorectal cancer
- Endometrial cancer
- Melanoma
- Pancreatic cancer
This test is not intended to screen comprehensively for all cancers.
What you will get
- A report with results provided to your physician
- A complimentary call with one of our genetic counselors to review your results upon request (currently applies to U.S only)
- Insights to help you and your physician determine the most appropriate preventive, clinical, and lifestyle considerations based on your hereditary risk
- Comprehensive analysis of 26 genes associated with hereditary breast and ovarian cancer
What will you learn
- Help you understand your risk of developing breast, ovarian, and other cancer types
- Help identify potentially at-risk family members
- Improve the odds of early detection and prevention
- Help guide management and/or treatment options depending on which genes are involved
how to get started
- You talk with your physician about BRCA. After we receive your physicians order, we send you a link to secure payment site
- Once we receive your sample, we process it at our CLIA-certified lab and provide results within 3 to 4 weeks
- We let you and your physician know that your results are ready on our secure site
Targeted genes
- BRCA1 and BRCA2 along with 24 other genes known to be associated with increased risk for hereditary breast and/or ovarian cancer.
- This multi-gene panel test also includes genes known to be associated with an increased risk for other cancer types such as colorectal, pancreatic, gastric, endometrial and thyroid
- Genes cover several hereditary cancer syndromes including Cowden syndrome, Li-Fraumeni syndrome, Peutz-Jeghers syndrome, and Lynch syndrome
POSSIBLE OUTCOMES
- Any result, negative, positive or inconclusive, should become a part of how you and your physician evaluate your health and clinical needs
technical information
- Targeted next generation sequencing assay for 26 hereditary cancer genes
- Point variants and small insertions/deletions are detected (> 99.9% sensitivity and specificity), large rearrangement and deletion/ duplication analysis are also performed
- Likely pathogenic or pathogenic intronic variants up to 10 base pairs from the coding region are always reported
- Laboratory developed test (LDT) performed in a CLIA-certified laboratory (CLIA#22D2089381) following LDT regulations
- Variant classification based on American College of Medical Genetics and Genomics Guidelines
- PMS2 pseudogene analysis included
myBRCA HiRisk Hereditary Breast and Ovarian Cancer Panel
Targeted next generation sequencing and large rearrangement analysis in 26 genes
